Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc develops and commercializes cardiovascular therapeutics centered on icosapent ethyl, marketed as VASCEPA in the United States and VAZKEPA in Europe. Company news commonly covers product revenue, cash flow, U.S. prescription trends, partner-led international commercialization, and European distribution under an exclusive licensing and supply agreement with Recordati.
Updates also include medical-society guideline discussions, REDUCE-IT analyses, peer-reviewed publications, and scientific meeting presentations on cardiovascular risk reduction, elevated triglycerides, eicosapentaenoic acid, and lipoprotein(a) oxidation.
Amarin Corporation announces a conference call for discussing its fourth quarter and full year 2020 financial results on February 25, 2021, at 7:30 a.m. ET. This follows the anticipated release of financial results earlier that day. Investors can access the call via the company's website or by dialing the designated phone numbers. A replay will be available for two weeks thereafter. Questions can be submitted prior to the call via email, and management will respond to queries during the live session.
Amarin Corporation plc (NASDAQ:AMRN) announced that its partner Edding has initiated regulatory reviews for VASCEPA® (icosapent ethyl) in Mainland China and Hong Kong. The Chinese National Medical Products Administration has accepted VASCEPA's new drug application, with a decision expected by the end of 2021. Concurrently, Hong Kong's Department of Health is reviewing VASCEPA based on prior approvals in the U.S. and Canada. Both parties aim to provide this treatment option, highlighting its significance in combating cardiovascular disease in the region.
Amarin Corporation (NASDAQ:AMRN) announced a positive opinion from the CHMP of the EMA recommending marketing authorization for icosapent ethyl, branded as VAZKEPA, for reducing cardiovascular event risks in high-risk patients. This decision is based on over a decade of research, including the REDUCE-IT study, which showed a 25% relative risk reduction in major cardiovascular events among patients taking the drug. A European Commission decision is expected within 67 days, potentially granting ten years of market protection in the EU and extending exclusivity into 2039 through pending patents.
Amarin Corporation has expanded its patent infringement lawsuit against Hikma Pharmaceuticals to include Health Net, a health insurance provider, in the U.S. District Court in Delaware. The lawsuit claims Health Net has induced pharmacies to dispense Hikma's generic icosapent ethyl capsules, infringing on Amarin's patents for cardiovascular risk reduction. Amarin seeks a permanent injunction against these practices and monetary damages. The company emphasizes the significance of its patents in preventative cardiovascular care and plans to pursue the case vigorously, leveraging proceeds from VASCEPA sales.
Amarin Corporation plc (NASDAQ:AMRN) announced that icosapent ethyl has been included in the updated Guidelines for Primary Prevention of Cardiovascular Diseases by the Chinese Society of Cardiology (CSC) for 2021. The guidelines recommend icosapent ethyl 2 grams twice daily to reduce atherosclerotic cardiovascular disease (ASCVD) risk, highlighting its efficacy as shown in the REDUCE-IT study. With this inclusion, icosapent ethyl is now recognized by 13 medical associations worldwide. The CSC classification reflects strong evidence, underscoring the importance of this treatment for at-risk patients.
Amarin Corporation plc (NASDAQ:AMRN) announced preliminary unaudited total net revenue for 2020 estimated at $610 million, marking a 42% increase from 2019. This growth was primarily driven by increased prescriptions of VASCEPA® despite COVID-19 challenges. The company ended 2020 with over $550 million in cash and no debt. Amarin is preparing for the regulatory approval of VASCEPA in Europe and aims for a commercial launch in 2021. The company plans to present further details at the J.P. Morgan Healthcare Conference on January 12, 2021.
Amarin Corporation plc has announced that its president and CEO, John F. Thero, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, from 2:00 to 2:40 p.m. Eastern Time. A live audio webcast will be accessible at amarincorp.com for 30 days following the event.
Amarin focuses on cardiovascular health with its lead product, VASCEPA (icosapent ethyl), currently prescribed in the U.S., Canada, Lebanon, and the UAE. The company is pursuing further regulatory approvals in China, Europe, and the Middle East.
Amarin Corporation (NASDAQ:AMRN) presented critical findings related to VASCEPA® (icosapent ethyl) during the National Lipid Association Scientific Sessions 2020. Key highlights include a significant correlation between eicosapentaenoic acid (EPA) levels and improved cardiovascular outcomes, showcasing a 400% increase from baseline in a prominent trial. Additionally, the VASCEPA COVID-19 CardioLink-9 Trial indicated a 25% reduction in high-sensitivity C-reactive protein (hsCRP) among COVID-19 patients, suggesting VASCEPA may help alleviate symptoms while demonstrating good safety and tolerability.
Amarin Corporation announces positive results from the VASCEPA COVID-19 CardioLink-9 Trial, showcasing a 25% reduction in high-sensitivity C-reactive protein (hsCRP) and a 52% reduction in patient-reported COVID-19 symptoms compared to usual care. Conducted on 100 symptomatic outpatients, the trial demonstrated VASCEPA's potential as a therapeutic option in COVID-19, with promising short-term safety data. Larger follow-up studies are planned, expected to be completed by 2021. A webcast discussing these findings is scheduled for December 14, 2020.
Amarin Corporation has announced significant research findings to be showcased at the NLA Scientific Sessions 2020 from December 10-12, 2020. These include two Late Breaker presentations and six e-Posters centered on VASCEPA (icosapent ethyl), particularly its efficacy in cardiovascular risk reduction. Notably, the results from the COVID-19 CardioLink-9 trial will also be highlighted. Amarin emphasizes its commitment to support scientific research that explores the broader public health implications of VASCEPA.